Intervention planning for dengue requires reliable estimates of dengue transmission intensity. However, current
maps of dengue risk provide estimates of disease burden or the boundaries of endemicity rather than transmission
intensity. We therefore developed a global high-resolution map of dengue transmission intensity by fitting
environmentally driven geospatial models to geolocated force of infection estimates derived from cross-sectional
serological surveys and routine case surveillance data. We assessed the impact of interventions on dengue transmission and disease using Wolbachia-infected mosquitoes and the Sanofi-Pasteur vaccine as specific examples.
We predicted high transmission intensity in all continents straddling the tropics, with hot spots in South America
(Colombia, Venezuela, and Brazil), Africa (western and central African countries), and Southeast Asia (Thailand,
Indonesia, and the Philippines). We estimated that 105 [95% confidence interval (CI), 95 to 114] million dengue
infections occur each year with 51 (95% CI, 32 to 66) million febrile disease cases. Our analysis suggests that
transmission-blocking interventions such as Wolbachia, even at intermediate efficacy (50% transmission reduction), might reduce global annual disease incidence by up to 90%. The Sanofi-Pasteur vaccine, targeting only
seropositive recipients, might reduce global annual disease incidence by 20 to 30%, with the greatest impact in
high-transmission settings. The transmission intensity map presented here, and made available for download,
may help further assessment of the impact of dengue control interventions and prioritization of global public
health efforts.